Argos Therapeutics (ARGS) Earns Media Impact Rating of 0.12
Media coverage about Argos Therapeutics (NASDAQ:ARGS) has been trending somewhat positive recently, Accern reports. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Argos Therapeutics earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 44.9439558374934 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Argos Therapeutics (NASDAQ ARGS) traded down $0.09 during midday trading on Wednesday, hitting $1.48. 227,400 shares of the stock were exchanged, compared to its average volume of 884,475. The firm has a market cap of $9.64, a P/E ratio of -0.06 and a beta of 0.99. Argos Therapeutics has a 1 year low of $1.40 and a 1 year high of $98.00. The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of -1.46.
Separately, ValuEngine upgraded shares of Argos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating and three have given a hold rating to the company. Argos Therapeutics currently has an average rating of “Hold” and an average price target of $24.00.
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.